Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 12:9:898077.
doi: 10.3389/fvets.2022.898077. eCollection 2022.

Tolerability and Effects of 2-Aminoethyl Dihydrogen Phosphate in Dogs With Mast Cell Tumors

Affiliations

Tolerability and Effects of 2-Aminoethyl Dihydrogen Phosphate in Dogs With Mast Cell Tumors

Eric Vieira Januário et al. Front Vet Sci. .

Abstract

Canine mast cell tumor is a malignant neoplasm, and a gold standard treatment remains to be determined despite the proposed chemotherapies or other therapies in dogs. This study aimed to determine therapeutic, adverse effects and toxicity, tumor-free, and overall survival times of 10 dogs with surgically excised mast cell tumors evaluated by histopathological/immunohistochemistry and treated with four weekly intravenous administrations of 2-Aminoethyl Dihydrogen Phosphate (70 mg/kg) as adjuvant therapy. No adverse events were noted. Laboratory changes were limited (p < 0.05) in red blood cell, hemoglobin, and platelet counts. Mean tumor-free and overall survival were 599.1 ± 469 and 755.5 ± 423.5 days, respectively. In conclusion, 2-Aminoethyl Dihydrogen Phosphate administration was safe in dogs. However, 2-Aminoethyl Dihydrogen Phosphate was not sufficiently effective to prevent a recurrence, new tumor, or metastasis of canine mast cell tumors with poor immunohistochemical prognostic factors.

Keywords: antineoplastic phospholipids; canine; chemotherapy; immunohistochemistry; toxicity.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Kaplan-Meier survival curves of patients treated with 2-AEH2F.

Similar articles

References

    1. Finnie JW, Bostock DE. Skin neoplasia in dogs. Aust Vet J. (1979) 55:602–4. 10.1111/j.1751-0813.1979.tb07068.x - DOI - PubMed
    1. Misdorp W. Mast cells and canine mast cell tumours. A review. Vet Q. (2004) 26:156–69. 10.1080/01652176.2004.9695178 - DOI - PubMed
    1. Macy DW. Canine mast cell tumors. Vet Clin North Am Small Anim Pract. (1985) 15:783–803. 10.1016/S0195-5616(85)50036-4 - DOI - PubMed
    1. Murphy S, Sparkes AH, Blunden AS, Brearley MJ, Smith KC. Effects of stage and number of tumours on prognosis of dogs with cutaneous mast cell tumours. Vet Rec. (2006) 158:287–91. 10.1136/vr.158.9.287 - DOI - PubMed
    1. Kiupel M, Webster JD, Bailey KL, Best S, DeLay J, Detrisac CJ, et al. . Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior. Vet Pathol. (2011) 48:147–55. 10.1177/0300985810386469 - DOI - PMC - PubMed

LinkOut - more resources